Omega-3 Pufa and Aspirin as Adjunctive Therapy in Treatment of Smoker Patients With Stage Iii Periodontitis

Evaluation of the Use of Omega-3 Pufa and Aspirin as Adjunctive Therapy in the Treatment of Smoker Patients With Stage Iii Periodontitis (Randomized Clinical Trial)

Background: Smoking reduces the effect of non-surgical periodontal therapy, a host modulation regimen consisting of omega-3 polyunsaturated fatty acids (ω-3 PUFA) supplementation with low-dose aspirin (ASA) with or without systemic doxycycline has been proposed to improve treatment response.

The Aim of the study is to explore the clinical effects of orally administered omega-3 PUFA and ASA with or without systemic doxycycline with periodontal debridement in treatment of smoker individuals with stage III periodontitis.

Inclusion Criteria:

• Smoker patients who smoke ≥ 10 cigarettes per day.
• Stages III, Grades C periodontitis with at least one site with PD≥6 and CAL ≥5 mm.

Exclusion Criteria:

• Scaling and root planning in the previous 6 months(that may confound the effect of treatment)
• Antimicrobial therapy in the previous 6 months(that may confound the effect of treatment)
• Chronic systemic diseases that may have an impact on periodontitis progression (diabetes mellitus).
• Systemic diseases that may contraindicate aspirin or doxycycline taking (kidney and liver diseases)
• Allergy to doxycycline
• Long-term usage of medications that may impair periodontal health
• Allergy to fish/seafood